search
Back to results

Effect of Melatonin on Sleep Quality in Patients Dementia

Primary Purpose

Sleep Disorders, Dementia

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Melatonin 5 mg
Placebo
Sponsored by
Hospital Universitario Dr. Jose E. Gonzalez
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Disorders focused on measuring melatonin, sleep, dementia, cognition

Eligibility Criteria

60 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Older than 60 years;
  • Circadian cycle sleep disorder with insomnia (according to Diagnostic and Statistical Manual of Mental Disorders- V criteria);
  • Mild or moderate dementia (clinical dementia rating 1 and 2);
  • Medications such as anti-depressants, acetylcholinesterase inhibitors, antipsychotics or memantine were allowed as long as they were initiated for over 8 weeks.

Exclusion Criteria:

  • They had other diagnoses of sleep disorders, known hypersensitivity to melatonin, use of stimulants or hypnotics, recent diagnosis (within 8 weeks) of mood disorders or neuropsychiatric symptoms.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Placebo Comparator

    Arm Label

    Melatonin

    placebo

    Arm Description

    Melatonin 5 mg, daily, eight weeks

    Placebo, daily, eight weeks

    Outcomes

    Primary Outcome Measures

    Pittsburgh Sleep Quality Index
    A self-administered questionnaire that provides an overall rating of sleep quality.

    Secondary Outcome Measures

    Minimental test
    The original purpose is to allow physicians to standardize and quantify cognitive status.

    Full Information

    First Posted
    February 19, 2017
    Last Updated
    February 23, 2017
    Sponsor
    Hospital Universitario Dr. Jose E. Gonzalez
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03066518
    Brief Title
    Effect of Melatonin on Sleep Quality in Patients Dementia
    Official Title
    A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    January 15, 2016 (Actual)
    Primary Completion Date
    January 25, 2017 (Actual)
    Study Completion Date
    January 25, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Hospital Universitario Dr. Jose E. Gonzalez

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Introduction: Patients with dementia may suffer from poor sleep quality. Disturbance in the metabolism melatonin may have a role in the pathogenesis of sleep-wake cycle alterations in dementia. Objective: To evaluate the efficacy of low dose exogenous melatonin in improving sleep quality. Design: A single-center randomized, double-blinded, placebo-controlled study carried out on outpatients with dementia and sleep alterations. Participants: The investigators calculated a 40 individuals aged 65 years or over with a diagnosis of mild-moderate dementia (Clinical Dementia Rating 1-2). Intervention: Patients were randomized to receive either 5 mg of melatonin or placebo every night for 8 weeks. Measurements: The primary outcome was sleep quality according to the Pittsburgh Sleep Quality Index (PSQI).
    Detailed Description
    This is a single-center study. The study protocol, informed consents, and amendments were approved in writing by the appropriate local site Independent Ethics Committee (IEC)/Institutional Review Boards (IRB) (Ethics Committee of the Universidad Autónoma de Nuevo León, School of Medicine). The patients were recruited as outpatients from the Geriatrics Clinic. A total of 67 patients were screened out of which 40 male and female patients diagnosed with mild to moderate dementia were recruited to the study. Following inclusion, all patients underwent randomization to treatment with melatonin (5 mg orally) or placebo for 8 weeks. To prevent bias, matching placebo tablets, which were identical in appearance, taste, and odor, were used. The treatment was double-blinded, with two parallel treatment groups. Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Sleep Disorders, Dementia
    Keywords
    melatonin, sleep, dementia, cognition

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Model Description
    A randomized, double-blinded, placebo-controlled study
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Masking Description
    Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.
    Allocation
    Randomized
    Enrollment
    40 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Melatonin
    Arm Type
    Placebo Comparator
    Arm Description
    Melatonin 5 mg, daily, eight weeks
    Arm Title
    placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo, daily, eight weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Melatonin 5 mg
    Other Intervention Name(s)
    Benedorm
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Pittsburgh Sleep Quality Index
    Description
    A self-administered questionnaire that provides an overall rating of sleep quality.
    Time Frame
    8 weeks
    Secondary Outcome Measure Information:
    Title
    Minimental test
    Description
    The original purpose is to allow physicians to standardize and quantify cognitive status.
    Time Frame
    baseline and to the 8 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    60 Years
    Maximum Age & Unit of Time
    95 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Older than 60 years; Circadian cycle sleep disorder with insomnia (according to Diagnostic and Statistical Manual of Mental Disorders- V criteria); Mild or moderate dementia (clinical dementia rating 1 and 2); Medications such as anti-depressants, acetylcholinesterase inhibitors, antipsychotics or memantine were allowed as long as they were initiated for over 8 weeks. Exclusion Criteria: They had other diagnoses of sleep disorders, known hypersensitivity to melatonin, use of stimulants or hypnotics, recent diagnosis (within 8 weeks) of mood disorders or neuropsychiatric symptoms.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Guillermo Guajardo, MD
    Organizational Affiliation
    HUGonzález
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    21225347
    Citation
    Crowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011 Mar;21(1):41-53. doi: 10.1007/s11065-010-9154-6. Epub 2011 Jan 12.
    Results Reference
    background
    PubMed Identifier
    19738366
    Citation
    Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181-9. doi: 10.1159/000236900. Epub 2009 Sep 9.
    Results Reference
    background
    PubMed Identifier
    19426575
    Citation
    Beaulieu-Bonneau S, Hudon C. Sleep disturbances in older adults with mild cognitive impairment. Int Psychogeriatr. 2009 Aug;21(4):654-66. doi: 10.1017/S1041610209009120. Epub 2009 May 11.
    Results Reference
    background
    PubMed Identifier
    21417189
    Citation
    Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs. 2011 Oct;4(4):281-93. doi: 10.3928/19404921-20110302-01. Epub 2011 Mar 16.
    Results Reference
    background
    PubMed Identifier
    26742676
    Citation
    Guarnieri B, Cerroni G, Sorbi S. Sleep disturbances and cognitive decline: recommendations on clinical assessment and the management. Arch Ital Biol. 2015 Jun-Sep;153(2-3):225-30. doi: 10.12871/0003982920152347.
    Results Reference
    background
    PubMed Identifier
    27476067
    Citation
    Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol. 2016 Sep;18(9):40. doi: 10.1007/s11940-016-0424-3.
    Results Reference
    background
    PubMed Identifier
    25614508
    Citation
    Xu J, Wang LL, Dammer EB, Li CB, Xu G, Chen SD, Wang G. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):439-47. doi: 10.1177/1533317514568005.
    Results Reference
    background
    PubMed Identifier
    27851868
    Citation
    McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3.
    Results Reference
    background
    PubMed Identifier
    25515275
    Citation
    Chien MY, Chen HC. Poor sleep quality is independently associated with physical disability in older adults. J Clin Sleep Med. 2015 Mar 15;11(3):225-32. doi: 10.5664/jcsm.4532.
    Results Reference
    background
    PubMed Identifier
    33189083
    Citation
    McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020 Nov 15;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub4.
    Results Reference
    derived
    PubMed Identifier
    34674490
    Citation
    Morales-Delgado R, Camara-Lemarroy CR, Salinas-Martinez R, Gamez-Trevino D, Arredondo-Jaime A, Hernandez-Maldonado E, Guajardo-Alvarez G. A randomized placebo-controlled trial evaluating the effect of melatonin on sleep quality in patients with mild-moderate dementia. Eur Geriatr Med. 2018 Aug;9(4):449-454. doi: 10.1007/s41999-018-0068-9. Epub 2018 May 24.
    Results Reference
    derived

    Learn more about this trial

    Effect of Melatonin on Sleep Quality in Patients Dementia

    We'll reach out to this number within 24 hrs